Bright Minds Biosciences
DRUG
9 hedge funds and large institutions have $257K invested in Bright Minds Biosciences in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.16% more ownership
Funds ownership: 0.68% → 0.84% (+0.16%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
17% less capital invested
Capital invested by funds: $310K → $257K (-$52.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$89K |
| 2 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$30.6K |
| 3 |
Renaissance Technologies
New York
|
+$18.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.77K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$143 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$29K |
| 2 |
SG
StoneX Group
New York
|
-$7.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $198K | +$89K | +26,858 | +43% |
|
|
SS
2
Simplicity Solutions
Minneapolis,
Minnesota
| $20.3K | +$30.6K | +9,241 | New |
|
|
3
Renaissance Technologies
New York
| $12K | +$18.4K | +5,541 | New |
|
|
QFA
4
Quattro Financial Advisors
The Woodlands,
Texas
| $9.31K | – | – | – |
|
|
CCA
5
Checchi Capital Advisers
Beverly Hills,
California
| $6.22K | – | – | – |
|
6
BlackRock
New York
| $5.19K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $4.8K | +$3.77K | +1,138 | +109% |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$143 | +43 | +12% |
|
|
APC
9
Aspire Private Capital
Cornelius,
North Carolina
| $220 | – | – | – |
|
|
VF
10
Virtu Financial
New York
| – | -$29K | -7,743 | Closed |
|
|
SG
11
StoneX Group
New York
| – | -$7.54K | -2,039 | Closed |
|
DRUG Hedge Fund Activity: Q1 2023 in Review
9 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2023, worth a combined $257K — down 17% from $310K a quarter earlier.
Fund positioning in DRUG was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $89K. The largest seller was Virtu Financial, exiting entirely with an estimated $29K sold.
- 9 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $257K of Bright Minds Biosciences stock for Q1 2023, down 17% quarter-over-quarter.
- 2 funds opened new Bright Minds Biosciences positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Bright Minds Biosciences buyer in Q1 2023 was AdvisorShares Investments, an estimated $89K added.
- The largest Bright Minds Biosciences seller in Q1 2023 was Virtu Financial, an estimated $29K sold.
Based on aggregated 13F filings for Q1 2023.